BSH 2018 | Primary CNS lymphoma: can we use MATRix immunochemo in the real world?
Christopher Fox
• 16 Apr 2018
MATRix immunochemotherapy induction therapy has produced promising results in the recent IELSG 32 trial (NCT01011920) for primary CNS lymphoma (PCNSL). However, here at the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK, Christopher Fox, MBChB(Hons), MRCP, FRCPath, of Nottingham University Hospitals NHS Trust, Nottingham, UK, raises the question of whether this data can be replicated in real world settings, particularly in difficult patient groups. Dr Fox highlights how recent data using MATRix for PCNSL in the real world has produced good results, suggesting that there is hope for MATRix therapy.
